Tegavivint for the Treatment of Solid Tumors, Lymphomas & Desmoids

AddtoAny
Share:

WATCH THIS PAGE

Subscribe to be notified of changes or updates to this page.

4 + 14 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.

This study has two parts. Part A enrolls patients who have been diagnosed with a solid tumor, lymphoma or desmoid tumor that has either come back ("relapsed") or does not respond to therapy ("is refractory"). Part B enrolls patients with a relapsed or refractory Ewing sarcoma, desmoid tumor, osteosarcoma, liver tumor, Wilms tumor, or tumors with changes in a gene family known as the Wnt pathway. This study involves taking a study drug called tegavivint. The study will be testing different doses of the study drug to find the safest dose.

Who Do I Contact?

If you are interested in participating in the study or want to learn more please contact our study team at CancerTrials [at] CHOP.edu or 267-425-5544.

ClinicalTrials.gov Identifier

NCT04851119

View full trial information on ClinicalTrials.gov

Eligibility & Criteria

IRB #:
21-019434
Official Title:
PEPN2011; A Phase 1/2 Study of Tegavivint (IND#156033, NSC#826393) in Children, Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Study Phase:
Phase I
Phase II
Eligible Age Range:
12 Months - 30 Years
Gender:
All
Study Categories:

Visit Criteria

Participants in the research will:

  • Receive a study drug called tegavivint
  • Completete frequent clinic visits at CHOP
  • Have frequent blood tests
  • Have DEXA scans to measure your bone density
  • Have knee x-rays if under the age of 18
  • Have extra or leftover tissue collected if they have a biopsy as part of regular cancer care
  • Have periodic electrocardiograms (ECGs)
Leader
Theodore W. Laetsch

Theodore Laetsch, MD